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Abstract
Objective: To identify and explore differences in spending and utilization of key
health services at the end of life among hip fracture patients across seven developed
countries.
Data Sources: Individual-level claims data from the inpatient and outpatient health
care sectors compiled by the International Collaborative on Costs, Outcomes, and
Needs in Care (ICCONIC).
Study Design: We retrospectively analyzed utilization and spending from acute hos-
pital care, emergency department, outpatient primary care and specialty physician
visits, and outpatient drugs. Patterns of spending and utilization were compared in
the last 30, 90, and 180 days across Australia, Canada, England, Germany,
New Zealand, Spain, and the United States. We employed linear regression models
to measure age- and sex-specific effects within and across countries. In addition, we
analyzed hospital-centricity, that is, the days spent in hospital and site of death.
Data Collection/Extraction Methods: We identified patients who sustained a hip
fracture in 2016 and died within 12 months from date of admission.
Principal Findings: Resource use, costs, and the proportion of deaths in hospital
showed large variability being high in England and Spain, while low in New Zealand.
Days in hospital significantly decreased with increasing age in Canada, Germany,
Spain, and the United States. Hospital spending near date of death was significantly
lower for women in Canada, Germany, and the United States. The age gradient and
the sex effect were less pronounced in utilization and spending of emergency care,
outpatient care, and drugs.
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Conclusions: Across seven countries, we find important variations in end-of-life care
for patients who sustained a hip fracture, with some differences explained by sex and
age. Our work sheds important insights that may help ongoing health policy discus-
sions on equity, efficiency, and reimbursement in health care systems.
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What is known on this topic
• Countries follow different approaches to providing end-of-life care.
• Health care spending and utilization increases near death.
• International studies of health systems mainly compare acute hospital care and therefore lack
to account for different organization of end-of-life care.
What this study adds
• End-of-life care in the United States occurs more with specialists than in primary care, which
is in fundamental contrast to other countries.
• In most countries, health care spending and utilization decreases with age and is lower for
women.
1 | INTRODUCTION
Health policy makers have a strong interest in developing a better
understanding of how they can improve end-of-life care.1–3 Prior
studies have found that in the months leading to death, the need and
the costs of care increase substantially, and the bulk of these expendi-
tures come from high-acuity, high-cost individuals, such as those with
persistent chronic conditions.4–6 In addition, there are serious con-
cerns that the quality of care at the end of life often falls short of
expectations.7–9 As more people reach old age with chronic and dis-
abling conditions, improving the quality and efficiency of care at the
end of life will continue to grow as a priority policy issue.10 As such,
end-of-life care has become an important dimension of how we mea-
sure health system performance.11
International comparisons on end-of-life care may yield important
insights into how policy makers could improve the efficiency and the
quality of care. Such research is vital in setting performance benchmarks
and establishing best practice models from a system-wide and policy per-
spective. However, to date, comparisons at the end of life across coun-
tries are quite limited, especially when it comes to comparing robust data
across more than two countries and across different health care sectors.
In recent years, there have been significant advances in data infra-
structure across many countries that enable international
comparative research. This development is particularly true for patient-
level data, which is necessary to examine potential differences in end-
of-life care. Much of the relevant data are routinely collected through
administrative datasets, which are increasingly accessible for research
and quality improvement purposes.12 For example, claims data from
health care payers, such as health insurers or national health services,
provide a solid starting point for international comparisons as shown in
several international projects such as Health Basket13 and EuroDRG.14
In this study, as part of the International Collaborative on Costs,
Outcomes, and Needs in Care (ICCONIC) project, which is a research
collaborative across a set of high-income countries, we sought to eval-
uate differences in treatment at the end of life among frail, older
adults who sustained a hip fracture across seven countries as follows:
Australia, Canada, England, Germany, New Zealand, Spain, and the
United States. Specifically, we sought to examine differences in utili-
zation and spending across key health care services, including hospital
care, emergency care, primary care and outpatient specialty care, and
pharmaceuticals. Using a framework analyzing hip fracture patients,
our goal was to provide insight into how health systems can optimally
address the needs of the frail decedents by effectively accounting for
resource constraints.
2 | SUMMARY OF PREVIOUS
INTERNATIONAL STUDIES ON
END-OF-LIFE CARE
There is an extensive literature on the health care costs associated with
end-of-life care. Numerous studies have shown that health care costs
increase manifold in the time leading up to death.15–17 Riley and
Lubitz,18 for example, find that although decedents account for only 5%
of the US Medicare population in any given year, expenditure on this
group explains more than 25% of total Medicare expenditure. As has
been shown, the bulk of these expenditures come from high-need high-
cost individuals, such as those with persistent chronic conditions.19
The high costs at the end of life have led the policy makers to
question if health systems are obtaining value for money in end-of-
life care—particularly when considering that quality of care remains
far from optimal.20–23 At the same time, there is growing evidence
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that not all patients at the end of life face the same cost
trajectory.24–26 These studies show that there is considerable
heterogeneity in the pattern in health care use and associated costs
at the of end of life among different patients. Some patients face
very high and persistent costs over an extended period of time, and
others face a sudden decline in health status and associated rise in
health care costs over a very short period of time.27 As a result,
there are widening calls to develop a greater understanding the
drivers of end-of-life costs.
Another area of importance to health policy makers is awareness
of gender and age disparities, including in end-of-life care. While liter-
ature found gender disparities in end-of-life spending and utilization,
the direction of the disparity is not always consistent.28–30 Some stud-
ies show that women receive less aggressive treatment than men
receive when it comes to cancer or care in intensive care units. One
potential reason is that women are more likely to have a do-not-
resuscitate order than men.31–33 In addition, other work has found
that end-of-life spending at least in the United States declines with
age, indicating declining treatment intensity.28 Thus, while there is
some evidence in the area of cancer care, the evidence for frail elders
with a hip fracture, while similarly important, is less established.
Further, cultural factors can influence utilization of health services. In
some countries, there is variation in the proportion of older adults
who live alone versus live with other family members. In the United
States, evidence suggests that older adults are more likely to live
alone than other countries and, therefore, may have a limited support
system to care for themselves safely at home (and thus end up in a
skilled nursing facility).34 We therefore aim to expand on this litera-
ture and, importantly, show some consistency in patterns across coun-
tries by these important demographics.
Health policy makers who shape the health system have a strong
interest in understanding how different countries provide end-of-life
care, including current work at the Organisation for Economic
Co-operation and Development (OECD). The international evidence
on end-of-life care is limited—especially when it comes to comparing
robust data across more than two countries. There are two notable
exceptions. The first is French et al.5 who estimated the cost of care
in the last 30 and 365 days of life across nine countries. This study
found that mean cost in the last 12 months of life varied from US$
50,000 in Germany to over US$80,000. Noting that the study was
unable to control for the cause of death nor report on utilization. The
second exception is Bekelman et al.7 who examined hospital and che-
motherapy use and cost in seven countries in the last 180 days of life
for patients who died with cancer. The study found that mean per
capita hospital expenditures were highest in Canada (US$ 21,840) and
lowest in England (US$ 9342). Whilst Bekelman et al.7 focused on a
relatively homogenous patient group, the study was restricted to esti-
mating costs in a sub-set of the health care sector—albeit very impor-
tant sector.
This project builds on previous work and makes a considerable
contribution to developing a better understanding of internationally
comparable end-of-life costs and health care use. To the best of our
knowledge, this is the first study that has examined the end-of-life
costs for frail elderly patients who have experienced a hip fracture in
the last year of their life. This focus will provide new insights into
end-of-life costs for a relatively homogeneous group of frail elderly
patients who—due to their clinical condition—may be less likely to be
cared for in a palliative care setting.
Frail elderly hip fracture patients are a vulnerable patient group
with a high mortality rate following on from their hip fracture35 and
likely to incur significant health care costs.36 Using standardized codes
to identify a relatively frail and homogeneous group of patients, this
article reports on a broad range of health care costs and utilization
measures in seven countries and develops country-specific estimates
of these costs at various time points in the months leading up to
death.
3 | METHODS
3.1 | Data sources
We used patient-level data of seven out of the eleven countries par-
ticipating in the ICCONIC collaborative, that is, all countries that could
determine the exact date of death, to examine end-of-life utilization,
and spending as follows: Australia (AU), Canada (CA), England (EN),
Germany (DE), New Zealand (NZ), Spain (ES), and the United States
(US). Extracted utilization and spending data of Australia, Canada,
Germany, Spain, and the United States are based on individual-level
claims data from 2015 to 2017, while England and New Zealand used
a longer identification period. For specific details of each country's
dataset, please see Appendix 1 and Figueroa et al.37
3.2 | Patient selection
We followed a two-step approach to identify a comparable set of
frail elders who received treatment for a hip fracture. Hip fracture
has been commonly used as a reliable marker of frailty among older
adults,38 and it accounts for the majority of fractures related to fra-
gility globally.39 Hip fracture is also highly associated with physical
and mental disability, high mortality, and increased costs, thus
requiring considerable health care resources from different parts of
the health system.39–42 As hip fractures almost always require a hos-
pital admission and usually require surgery, the majority will be
recorded in hospital admissions data and can thus serve as a robust
and reliable tracer condition to explore differences in resource use
across health systems.38 We first identified a sample of comparable
patients by examining all patients who received a primary diagnosis
of hip fracture (S72.0-2 according to the International Classification
of Diseases version 10) in 2016 and obtained a total hip replace-
ment, a partial hip replacement, or were treated with an
osteosynthesis method such as screw, plate, pin osteosynthesis, or
internal fixation (see Appendix 2). From this sample, we identified
those who died within 365 days from the index hospitalization asso-
ciated with the hip fracture.
BLANKART ET AL. 3Health Services Research
3.3 | Spending and utilization measures
We followed a federated data extraction approach due to data
protection reasons. Each country produced means of utilization and
spending by sex and age (65–69, 70–74, 75–79, 80–84, 85–89,
90–94, and older than 95 years), from individual patient-level data.
These aggregated nonidentifiable data were then collected in a cen-
tral database for the analysis. It is important to note that we used
the perspective of the health care payer across all countries. In most
countries, this is either directly by an insurance or sickness fund
(Germany and the Netherlands) or directly from a national form of
health insurance (United States with Medicare program, Canada,
etc.). Therefore, our study does not capture full costs (as it does not
account for the fixed costs of all structures within a health system).
It only captures were actually paid for the services, which across all
countries, already included the fixed costs of the system. In order to
compare spending reliably, we first applied the OECD Actual
Individual Consumption Purchasing Power Parities (AIC PPPs) to
the expenditure data. AIC PPPs, rather than gross domestic
product–based purchasing power parities, are currently used by the
OECD as the most reliable economy-wide conversion rates for
health expenditure.43 Across each country, we applied 2017 AIC
PPPs to all expenditures using the following exchange rates as
follows: 1 AU$ ≙ US$ 0.69, 1 CA$ ≙ US$ 0.83, 1 GBP ≙ US$ 1.45,
1 EUR (Germany) ≙ US$ 1.33, 1 NZ$ ≙ US$ 0.69, 1 EUR
(Spain) ≙ US$ 1.56, and US$ 1 ≙ US$ 1.37 Similar to Bekelman
et al.,7 we calculated average utilization and average spending for
acute hospital care, emergency department admissions, excluding
observation stays, primary and specialist outpatient physician ser-
vices, including the services of nurse practitioners in Australia,
Canada, and the United States and outpatient drugs for the periods
of 30, 90, and 180 days before death (see Figure 1A). Utilization and
spending were allocated proportionally to the observation periods in
case of accruals (see Figure 1B).
3.4 | Data analysis
First, we described the number of decedents by country and sex.
From each country's total sample of elderly patients who have experi-
enced a hip fracture, we calculate the proportion of people who have
died within 365 days of the fracture.44 We also calculated the propor-
tion of decedents in hospital relative to those who are discharged
after their hip fracture admission.
To analyze within- and between-country variation, we esti-
mate utilization and spending yi as a function of country-fixed
death
time
30 days before 
death
90 days before 
death




Hospital stay (40 days)
attributed to
90-days period
not attributed to 
90-days period
22 days 18 days




F IGURE 1 (A) Utilization and
spending included in the analyses of
30, 90, and 180 days before death
and (B) calculation of utilization and
costs in case of accruals at the
example of the 90-day period
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effects to determine baseline utilization and baseline spending,
respectively. In addition, we include the interaction of country and
sex, the interaction of country and age group, which we coded
ascendingly from 1 to 7 for the 65–70 years to the older than
95 group, and the interaction of country and days before death into
the model to disentangle potential country-specific effects of sex,
age, and time. We fitted the model with no intercept term and,
therefore, the age group and country estimates refer to zero, that is,
we needed no reference group. We define the following six depen-
dent variables for utilization as follows: acute hospital admissions,
days in hospital, emergency department visits, medical doctor spe-
cialist visits, primary care visits, and outpatient prescription drugs. In
addition, we measure the following five dependent variables spend-
ing as follows: acute hospital stays, emergency department, special-
ists, and primary care visits, as well as for outpatient prescription
drugs. We estimate for each dependent variable the following linear
regression:
yi ¼ xiβ þ xi sexϕ þ xi age γ þ xi time τ þ ε
where xi denotes a vector of country-fixed effects and ε is a normally
distributed error term. We obtaine β indicating baseline utilization and
spending, ϕ sex-specific utilization and spending, γ an age gradient,
and τ time-dependent utilization and spending. We considered
p<0:05 as statistically significant throughout the whole paper. All
estimations were using the statistical program R 4.0.3 and the inte-
grated lm function for linear regression.45
4 | RESULTS
4.1 | Descriptive statistics
A total of 16,482 decedents were observed across the seven coun-
tries. In relation to the main cohort,37 between 23.0% and 31.6% of
all frail elders died within 365 days after a hip fracture across coun-
tries. Across all countries, more women (10,588) than men (5894) died
after the event in absolute terms, but the relative mortality of women
was lower than that of men. Mortality ranged for women between
TABLE 2 Utilization and spending by country during 30, 90, and 180 days before death




























30 days before death
Australia 0.45 4.2 0.07 0.78 2.1 2.0 6937 39 112 107 120
Canada 0.84 9.2 0.16 0.78 2.5 6.6 11,611 60 94 187 219
England 0.94 12.7 0.08 0.40 2.1 6.0 7982 48 83 87 212
Germany 0.93 9.6 - 0.58 0.6 3.6 8094 - 88 102 238
New Zealand 0.68 4.9 0.03 0.13 - 8.7 4942 8 21 - 143
Spain 1.03 14.8 1.05 2.10 2.7 5.2 9089 226 284 174 236
United States 0.77 5.4 0.24 0.71 0.3 3.6 11,109 276 241 87 267
90 days before death
Australia 0.97 8.7 0.16 1.73 5.2 4.4 13,805 79 209 247 372
Canada 1.28 17.1 0.40 2.14 5.9 10.1 19,356 135 242 389 648
England 1.54 24.2 0.18 1.40 4.7 10.0 12,909 97 259 187 660
Germany 1.51 19.5 - 1.61 1.5 7.9 14,092 - 249 318 688
New Zealand 1.18 9.7 0.08 0.46 - 13.1 9485 19 88 - 323
Spain 1.38 21.7 1.68 4.22 6.8 9.1 13,802 363 467 423 609
United States 1.31 9.7 0.52 2.29 1.0 7.5 18,867 625 977 321 914
180 days before death
Australia 1.56 13.3 0.28 2.85 9.4 7.3 20,200 129 329 422 722
Canada 1.72 24.0 0.70 4.15 9.5 12.7 25,839 229 456 626 1291
England 2.20 32.5 0.31 2.65 7.9 12.2 16,503 158 504 312 1325
Germany 2.07 27.5 - 3.13 2.8 10.8 18,931 - 492 594 1274
New Zealand 1.64 13.1 0.15 0.95 - 15.8 12,827 33 190 - 576
Spain 1.71 26.6 2.24 6.40 11.7 10.9 17,427 483 689 712 1193
United States 1.80 13.2 0.82 4.66 2.2 10.4 25,336 997 2156 696 1923
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Australia 0.41 (0.24) . 6.05 (3.73) 0.04 (0.16) 2.79 (1.7) 0.02 (1.96) 1.98 (1.07) .
Canada 1.17 (0.15)*** 16.3 (2.27)*** 0.22 (0.09)* 1.37 (1.03) 1.65 (0.62)** 5.6 (0.65)***
England 1.27 (0.15)*** 8.99 (2.27)*** 0.1 (0.09) 1.79 (1.03) . 1.05 (0.62) . 6.53 (0.65)***
Germany 1.32 (0.15)*** 16.43 (2.27)*** - 0.29 (1.03) 0.05 (0.62) 2.8 (0.65)***
New Zealand 0.6 (0.15)*** 5.45 (2.27)* 0 (0.09) 0.28 (1.03) - 7.72 (0.65)***
Spain 0.89 (0.15)*** 22.98 (2.27)*** 1.14 (0.09)*** 3.2 (1.03)** 1.12 (0.62) . 3.93 (0.65)***
United States 1.17 (0.24)*** 11.27 (3.73)** 0.4 (0.16)* 2.1 (1.7) 0.18 (1.01) 4.47 (1.07)***
Sex effect (female = 1)
Australia 0.09 (0.17) 1.45 (2.64) 0.07 (0.111) 2.18 (1.202) . 0.77 (0.719) 0.57 (0.756)
Canada 0.06 (0.1) 3.11 (1.55)* 0.07 (0.065) 0.23 (0.703) 0.6 (0.42) 0.82 (0.442) .
England 0.12 (0.1) 0.46 (1.55) 0 (0.065) 0.83 (0.703) 0.66 (0.42) 1.11 (0.442)*
Germany 0.09 (0.1) 2.52 (1.55) - 0.36 (0.703) 0.01 (0.42) 0.35 (0.442)
New Zealand 0.25 (0.1)* 2.27 (1.55) 0.03 (0.065) 0.21 (0.703) - 0.56 (0.442)
Spain 0.01 (0.1) 8.87 (1.55)*** 0.07 (0.065) 0.78 (0.703) 1.28 (0.42)** 1.17 (0.442)**
United States 0.15 (0.17) 2.03 (2.64) 0.05 (0.111) 0.41 (1.202) 0.02 (0.719) 0.07 (0.756)
Age effect
Australia 0.04 (0.02) . 0.38 (0.39) 0.01 (0.02) 1.122 (0.18)*** 0.017 (0.02) 0.11 (0.11)
Canada 0.1 (0.02)*** 1.71 (0.39)*** 0.05 (0.02)** 0.294 (0.18) . 0.185 (0.11) . 0.13 (0.11)
England 0.16 (0.02)*** 0.18 (0.39) 0.015 (0.02) 0.358 (0.18)* 0.065 (0.11) 0.45 (0.11)***
Germany 0.11 (0.02)*** 1.76 (0.39)*** - 0.019 (0.18) 0.024 (0.11) 0.1 (0.11)
New Zealand 0.01 (0.02) 0.1 (0.39) 0 (0.02) 0.034 (0.18) - 0.07 (0.11)
Spain 0.01 (0.02) 1.46 (0.39)*** 0.071 (0.02)*** 0.534 (0.18)** 0.145 (0.11) 0.06 (0.11)
United States 0.09 (0.02)*** 1.03 (0.39)** 0.048 (0.02)** 0.439 (0.18)* 0.059 (0.11) 0.44 (0.11)***
Time effect
Australia 0.009 (0.001)*** 0.06 (0.02)** 0.001 (0.001) 0.041 (0.01)*** 0.044 (0.006)*** 0.034 (0.006)***
Canada 0.006 (0.001)*** 0.11 (0.01)*** 0.004 (0.001)*** 0.025 (0.006)*** 0.05 (0.003)*** 0.042 (0.004)***
England 0.011 (0.001)*** 0.13 (0.01)*** 0.002 (0.001)** 0.02 (0.006)*** 0.037 (0.003)*** 0.043 (0.004)***
Germany 0.008 (0.001)*** 0.13 (0.01)*** - 0.018 (0.006)** 0.015 (0.003)*** 0.048 (0.004)***
New Zealand 0.007 (0.001)*** 0.06 (0.01)*** 0.001 (0.001) . 0.006 (0.006) - 0.047 (0.004)***
Spain 0.004 (0.001)*** 0.09 (0.01)*** 0.007 (0.001)*** 0.027 (0.006)*** 0.054 (0.003)*** 0.03 (0.004)***
United States 0.006 (0.001)*** 0.04 (0.02)* 0.004 (0.001)*** 0.029 (0.01)** 0.013 (0.006)* 0.047 (0.006)***
Root mean squared error 0.30 4.76 0.20 2.17 1.31 1.36















Australia 12,681 (2593.5)*** 31.9 (46.4) 198.5 (279.7) 117.9 (76.4) 496.9 (263.5) .
Canada 21,305 (1578.3)*** 73.6 (28.2)** 152.8 (170.2) 102.2 (46.5)* 403.1 (160.4)*
England 8062 (1578.3)*** 56.7 (28.2)* 288.6 (170.2) . 99.4 (46.5)* 93.2 (160.4)
Germany 17,322 (1578.3)*** - 265.3 (170.2) 67.8 (46.5) 619.1 (160.4)***
New Zealand 5350 (1578.3)*** 16 (28.2) 82 (170.2) - 143.6 (160.4)
Spain 3837 (1578.3)* 244.7 (28.2)*** 374.6 (170.2)* 50.6 (46.5) 215.3 (160.4)
United States 22,508 (2593.5)*** 519.9 (46.4)*** 1977.4 (279.7)*** 226.1 (76.4)** 1130.6 (263.5)***
(Continues)
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20.3% and 28.2% and for men between 29.5% and 40%. Next, we
observed distinct differences in hospital-based mortality: while in
Spain, 40% of patients died in hospital, in Australia, this occurred
in only 6.7% of patients. Across all countries, men had a higher likeli-
hood of dying in hospital (range 6.3%–49.7%) than women (range
7.1%–35.2%), while the variation across age groups was not pro-
nounced (Table 1).
The frail older adult with hip fracture was characterized by high
multimorbidity and high utilization of services across all countries.
Within the last 180 days before death, they received on average
across countries 11.4 different drug substances (range: 7.3 [AU] to
15.8 [NZ]). On average, they had 1.81 hospitalizations (range: 1.56
[AU] to 2.20 [EN]) and spent 21.5 days in hospital (range: 13.1 [NZ] to
32.5 [EN]). During the same period, the decedents visited specialists,
on average, 3.5 times (range: 0.95 [NZ] to 6.4 [ES]), primary care doc-
tors, 7.3 times (range: 2.2 [US] to 11.7 [ES]), and emergency
departments, 0.75 times (range: 0.15 [NZ] to 2.24 [ES]; see Table 2;
Appendices 3 and 4 show numbers by sex).
Across all countries, we observed relatively higher expenses in
the time interval closer to the date of death. Canada had the highest
hospital costs within 180 days (mean of US$ 25,839) with 44.9% of
this amount incurred in the last 30 days before death. All other coun-
tries similarly incurred the highest costs related to acute hospital care
within the last 30 days before death, ranging from 34.3% in Australia
to 52.2% in Spain. For the other spending categories, concentration of
costs in the last 30 days before death was much less pronounced.
4.2 | Regression results
Regression results with country-specific baseline utilization and















Sex effect (female = 1)
Australia 2811 (1836.9) 25.6 (32.8) 213.2 (198.1) 45.4 (54.1) 2.1 (186.7)
Canada 3618 (1074.4)*** 16.9 (19.2) 1.6 (115.9) 96.2 (31.6)** 26.5 (109.2)
England 1223 (1074.4) 0.6 (19.2) 55.2 (115.9) 25.4 (31.6) 92.3 (109.2)
Germany 2963 (1074.4)** - 56.5 (115.9) 24.2 (31.6) 70.8 (109.2)
New Zealand 2044 (1074.4) . 10.2 (19.2) 49.2 (115.9) - 65.1 (109.2)
Spain 771 (1074.4) 15 (19.2) 75.2 (115.9) 90.8 (31.6)** 131.6 (109.2)
United States 4030 (1836.9)* 60.8 (32.8) . 393.4 (198.1)* 20.1 (54.1) 156.1 (186.7)
Age effect
Australia 1152.6 (268.6)*** 1.8 (4.8) 87.4 (29)** 4.9 (7.9) 137.2 (27.3)***
Canada 2214 (268.6)*** 14.2 (4.8)** 33.5 (29) 11.3 (7.9) 105.9 (27.3)***
England 215.6 (268.6) 7.2 (4.8) 66.2 (29)* 14.8 (7.9) . 35.3 (27.3)
Germany 1981.8 (268.6)*** - 58.9 (29)* 13.7 (7.9) . 160 (27.3)***
New Zealand 57.9 (268.6) 0.8 (4.8) 14 (29) - 15.4 (27.3)
Spain 1184 (268.6)*** 15.2 (4.8)** 49.5 (29) . 2.9 (7.9) 55.3 (27.3)*
United States 1925.1 (268.6)*** 68.2 (4.8)*** 434.6 (29)*** 77.9 (7.9)*** 266.3 (27.3)***
Time effect
Australia 80.3 (14.9)*** 0.5 (0.3) . 4.1 (1.6)* 1.9 (0.4)*** 6.2 (1.5)***
Canada 105.7 (8.7)*** 1.3 (0.2)*** 2.8 (0.9)** 3.1 (0.3)*** 8.4 (0.9)***
England 61.6 (8.7)*** 0.8 (0.2)*** 3.7 (0.9)*** 1.5 (0.3)*** 7.4 (0.9)***
Germany 81.3 (8.7)*** - 3.3 (0.9)*** 3.2 (0.3)*** 8.9 (0.9)***
New Zealand 52.9 (8.7)*** 0.1 (0.2) 1 (0.9) - 3.1 (0.9)***
Spain 48.7 (8.7)*** 1.6 (0.2)*** 2.6 (0.9)** 3.2 (0.3)*** 5.7 (0.9)***
United States 77.2 (14.9)*** 4.8 (0.3)*** 15.2 (1.6)*** 5.1 (0.4)*** 12.7 (1.5)***
Root mean squared
error
3311.5 59.7 357.1 98.2 336.5
Adjusted R-squared 0.96 0.97 0.84 0.93 0.88
Note: “-” utilization/spending category not available in this country; significance codes: “***” = 0.001, “**” = 0.01, “*” = 0.05, “.” = 0.1.
Abbreviation: SE, standard errors.
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in Table 3. Root mean squared error ranges between 0.20 for emer-
gency department visits and 33,120 for hospital spending. Adjusted
R-squared ranges between 0.66 for specialist visits and 0.98 for drug
prescriptions. The estimates for baseline utilization and spending were
mainly positive and, for most countries, across all estimations, signifi-
cantly different from zero. This suggests that utilization and spending
not only depend on the number of days, but that there is a nonlinear
relationship between days before death and utilization and spending.
In some cases, females seem to receive less care than men. Females
had significantly less hospitalizations in New Zealand (0.25) and
spent less days in hospital in Canada (3.11) and Spain (8.87). The
sex effect on hospital expenditures is statistically significantly nega-
tive in Canada (US$ 3618), Germany (US$ 2963), and the United
States (US$ 4030), while the other countries also show a negative
but not significant coefficient at the 5% level. This suggests that
although women have an equally high utilization, they tend to receive
less expensive treatments in those countries. In the outpatient sector,
the situation is ambiguous: in the United States, specialist spending is
significantly lower for women (US$ 393.4), while primary care
spending is higher for women in Canada (US$ 96.2) and Spain (US$
90.8). The age gradient is almost always significantly negative for both
utilization and spending, suggesting significantly lower utilization
before death among older than younger people. The time effect is
consistently significantly positive as utilization and spending increase
with a longer the time horizon (see Table 3).
5 | DISCUSSION
International comparisons of end-of-life care for frail older adults
provide important insights as to how health systems manage com-
plex populations at the end of life. Using patient-level data linked
across inpatient and outpatient health care sectors, we found impor-
tant differences in how older adults with hip fracture are managed
across a group of seven high-income countries. We also shed
insights into how treatment intensity differences according to age,
sex, and time may explain some of the variation across countries. By
comparing expenditures relative to proximity of death, policy
makers may be able to identify opportunities to better allocate
scarce health care resources.
A key finding of this work is the large difference across countries
in the site of death, specifically whether it occurred in a hospital set-
ting or not. Site of death is increasingly becoming an important mea-
sure of health system performance, especially as prior studies have
shown that patients prefer dying at home,46,47 something that is not
the reality in most countries.48 In our study, England (36.5%) and
Spain (40%) are among the countries with the most decedents dying
in hospital. Australia and New Zealand, on the other hand, observed
the lowest rate of in hospital-based deaths at 6.7% and 12%. Similar
patterns regarding site of care have also been found elsewhere.7,49
The high rate in England seems to be related to unplanned hospital
care at the end of life,50 while the low rate in New Zealand may be
attributed to a historically strong focus on hospice and end-of-life
care, which limits the number of days a patient may spend in a hospi-
tal setting in their final days of life.51 Indeed, end-of-life care in
New Zealand tends to be provided in the home with the support of
homecare, medical, and hospice services. In cases where a higher level
of care may be needed, patients are cared for in a hospice facility or
an elderly care facility designed to provide specialized end-of-life sup-
port services.52 Furthermore, it is also important to not only consider
the site of death but also where the majority of end-of-life care took
place prior to the death.53 According to our data, the number of days
spent in hospital within the last month is strongly correlated with the
rate of decedents dying in the hospital, that is, the more days spent in
hospital care, the higher the in-hospital mortality rate. Further support
for specialized and community palliative care services may offer
patients and their carers more choice in deciding the most appropriate
site of death for them.47
We also observed important differences in the treatment by
health care sector at the end of life, which is a novel contribution to
previous international comparisons on end-of-life care. It was inter-
esting to observe that primary care visits play a much smaller role in
Germany (2.8) and the United States (2.2) than in the other countries,
where the average number of visits across Australia, Canada, England,
and Spain was 9.6 visits (range 9.4–11.7). With regard to specialist
visits, the United States is second with 4.7 visits, while in Germany, an
average of 3.1 specialist visits take place within the last 180 days of
life. The low number in Germany can be attributed to the reimburse-
ment system, where many services in the outpatient sector are flat
rate and bundled over a quarter. In the United States, however, it
seems that care at the end of life occurs more with specialists than
with primary care, which is a fundamental contrast to other countries
(e.g., Australia, Canada, England, and Spain) where the primary care
physician appears to assume a more prominent role. This is consistent
with overall patterns of utilization.54 Prescription drug use was high
across all countries, ranging from 7.3 unique type of scripts in
Australia to 15.8 in New Zealand. Spending on drugs, however, was
relatively modest and ranged from US$ 576 in New Zealand to US$
1923 in the United States in last 180 days of life.
Hospice use is organized very differently across countries and dif-
ficult to capture with our administrative data that are underlined by
the divergent data that are provided by Germany and the United
States (see Appendix 5 for utilization and spending). According to our
data, end-of-life patients spend, on average, 0.16 days in hospice in
Germany, while they spend 8.3 days in hospice in the United States.
In terms of hospital days, the situation is the opposite: in Germany,
decedents spend 9.6 days, and in the United States, only 5.4 days in
hospital during their last phase of life. In Australia, England, Germany,
and Spain, the decedents are very much supported by palliative care
teams that are based in the reference hospitals or are part of the pri-
mary care organization and therefore included in the inpatient and
specialist costs.55 Similarly, in New Zealand, end-of-life care is pro-
vided in the home, with the support of homecare, medical, and hos-
pice services, in a hospice if there are comorbidities that require
active care, or in an aged care facility, which is designed to provide
specialized end-of-life support services. However, the cost of aged
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care accommodation is often serviced by the patient, subject to an
asset assessment, with only limited costs coming from the public sec-
tor. These different organizational and reimbursement arrangements
make a direct comparison difficult, and our study based on administra-
tive data should be complemented by qualitative research to explore
the variation in the organization of hospice care further.
In most international comparisons, the United States typically has
the highest health care costs.56,57 Interestingly, this seems not to be
the case for end-of-life care in the acute hospital setting, while the
United States still has the highest health care costs across all other
spending categories analyzed in this study. This may also be reflective
of the fact that the use of advance care planning, and of end-of-life
directives, may be more limited in the United States as compared to
other countries. In previous work, Gupta et al.58 reported that among
US Medicare beneficiaries, the presence of an advanced care plan was
associated with less intensive health care utilization around the end of
life. Similar to our current findings reported, Bekelman et al.7 found in
their study of cancer patients that Canada had the highest end-of-life
hospital costs, while Germany had slightly lower costs than Canada.
This is not because the United States has fundamentally lower hospi-
tal costs but may reflect fewer inpatient hospital days in the United
States prior to death and likely more time during end-of-life care
spent in postacute rehabilitative facilities.54
We also encountered important differences across some coun-
tries in the treatment of people by age. Canada, Germany, and the
United States had the highest negative age gradients, that is, on aver-
age, these countries spend around US$ 2000 less per older age group.
In contrast, the age effect on spending did not play a role in
New Zealand and England across all health care services. This nega-
tive age gradient indicates that countries discriminate against age—
whether this addresses the patient needs to or due to efficiency
considerations. It is likely that spending is managed by differentiation
of the place of service delivery during the trajectories of care. The
study by Wodchis et al.59 on trajectories of care suggests that patients
are primarily transferred to home settings, that is, home, home rehab,
home nursing, and so forth, prior to death. Inpatient rehab plays a
subordinate role for decedents because if there is no chance of recov-
ery, they are not moved to these facilities; in Australia, Canada, and
Germany, for example, a decedent spends on average a very short
time in an inpatient rehabilitation unit during the last 30 days before
death (AU 0.86, CA 1.06, and DE 0.37 days). In the United States,
however, a decedent spends on average 7.41 days in inpatient reha-
bilitation, especially in skilled nursing homes. This effect, however,
converges when viewed over 90 and 180 days (see Appendix 5 for
utilization and spending). There are several reasons why this might be
the case. Patients have different accessibility to postacute rehabilita-
tive care and/or long-term care, which may influence the amount of
time spent in the hospital setting by age. In England, the National
Health Service does not cover these services, which limits the ability
of hospitals to discharge patients needing this type of care. In the
United States, patients are likely to be quickly discharged to postacute
rehabilitative care, while in Canada, patients have access to long-term
care. New Zealand, on the other hand, had relatively consistent
spending through the age groups, which as noted above, may be due
to the country's concerted and coordinated application of elder care
assessment services and support.
In part, the variation in use and costs across countries in each
health care sector (e.g., hospitals) may be driven by differences in the
roles and functions of that sector. For example, rehabilitation in some
countries may be a part of a hospital's routine functions—whereas in
other countries, much of this care may be provided in specialized
clinics or in the community. This implies that rehabilitation costs will
be incurred in the hospital sector for some countries, but in other
countries, it may be registered as an outpatient care. Such differences
in the roles and functions may be important drivers of the variation
seen between countries. The results reported in this article provide an
accurate description of costs and use within each sector, but further
work is needed to examine the reasons for that variation—which
includes further exploration of the roles and functions of each sector
as well as full data capture.
Finally, we observed that some countries spend less on treating
women before death. Specifically, while men and women generally
receive similar care in the outpatient setting, there appears to be some
differences in the type of care provided in the acute care setting, with
males receiving more expensive acute hospital end-of-life care across
countries. There are some potential factors that might explain this find-
ing. First, prior work has suggested that women may have a lower bio-
logical age than men and may therefore be less frail.60 There is also
some evidence that suggests men enter the last phase of life sicker than
women. For example, in Germany, male decedents scored a higher
Elixhauser mortality score61 than women. Second, it is possible that
there may be differences in preference of high-intensity treatments by
gender or in the offering of such treatments by clinicians. This effect has
been shown for other conditions, for example, Sharma et al.29 find that
men with advanced cancers are more likely than women to receive
aggressive, nonbeneficial care in the intensive care unit near death. Due
to the paucity of international studies on this topic, there is a limited
capacity to compare our results to others. In the few studies available,
there is some agreement in the results. In comparison to cancer patients,
for example, there were similar costs associated with acute care costs
but, perhaps not surprisingly, a much higher costs on outpatient care
compared to the patients in our sample.7 Further, in our study, we find
that the United States spends substantially more for patients at the end
of life after a hip fracture, which is consistent with the fact that they
spend more overall for this population and other populations like people
hospitalized with heart failure, even after adjusting for similar levels of
utilization. Our findings confirm that the United States has high prices
per unit across multiple care domains.
5.1 | Limitations
The study has limitations. First, we had to rely on a federated analysis
approach due to data protection regulations. Across countries, there
are differences in how data are structured and collected, which may
yield differences in the variables examined in this study. However, we
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used a patient vignette with specific diagnostic codes that are com-
monly used that should limit potential biases and deviations across
countries. Second, the federated approach did not allow us to perform
the estimations with individual-level data, which lower the efficiency
of our model; however, the coefficients should remain unbiased. The
small number of data points may also lead to a technical overfitting of
the regression. However, given that the data points are based on
thousands of observations, it still allows for a generalizability of the
conclusions. Third, the method applied ignores that spending may be
frontloaded during hospital stays in case of accruals (as illustrated in
Figure 1B). This leads to an overestimation of the actual hospital costs
incurred, most notably in the last 30 days before death. This is a prob-
lem of almost all claims data analyses and fades the longer the obser-
vation period is. Fourth, we used only a limited number of utilization
and spending categories, focusing on the most important categories
available and comparable across countries. Further research should
invest additional effort in detailing and identifying further categories
and making them comparable to complement our picture of the provi-
sion of end-of-life care. Fifth, when comparing absolute spending
across countries, we have to acknowledge that we compare prices but
do not account for the different economics of care delivery. We
explored the economic implications of different patterns of resource
use in the study of Lorenzoni et al.62 Lastly, we were unable to deter-
mine whether the differences in spending and utilization within and
between countries are due to differences in responsiveness to the
populations' demands, better allocative efficiency by countries, or
whether the end-of-life spending was potentially wasteful.25 Further,
we must be very careful with any causal conclusions based on the
data. Without taking the endogeneity issue and the health system
structures into account, it is very difficult to interpret the effects.37
Despite our significant progress in making the results as comparable
as possible, great care still needs to be taken in drawing conclusions
on the reasons for the cross-country variations.
6 | CONCLUSION
Across a group of seven high-income countries, we found important
variations in end-of-life care for patients who sustained a hip fracture,
with some differences explained by sex and age. Our work sheds
important insights that may help ongoing health policy discussions on
equity, efficiency, and reimbursement in health care systems. How-
ever, while our analysis has limitations, improved data capture and
availability might substantially increase the explanatory value of
international comparisons in the future.
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